<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1135-5727</journal-id>
<journal-title><![CDATA[Revista Española de Salud Pública]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Esp. Salud Publica]]></abbrev-journal-title>
<issn>1135-5727</issn>
<publisher>
<publisher-name><![CDATA[Ministerio de Sanidad]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1135-57272018000100505</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Costes sociales de las enfermedades ¿Cuán relevantes son para las evaluaciones económicas?]]></article-title>
<article-title xml:lang="en"><![CDATA[Social costs of diseases: How relevant are they for economic evaluations?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mareque]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oliva Moreno]]></surname>
<given-names><![CDATA[Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Pharmacoeconomics &amp; Outcomes Research Iberia (PORIB)  ]]></institution>
<addr-line><![CDATA[Pozuelo de Alarcón Madrid]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Carlos III Máster en Evaluación Sanitaria y Acceso al Mercado ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Castilla-La Mancha Departamento de Análisis Económico y Seminario de Economía y Salud ]]></institution>
<addr-line><![CDATA[Toledo ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2018</year>
</pub-date>
<volume>92</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1135-57272018000100505&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1135-57272018000100505&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1135-57272018000100505&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamentos: En el campo de la evaluación económica (EE), existe un debate abierto sobre la perspectiva más apropiada a aplicar. Pese a la relevancia del tema, apenas hay trabajos que analicen las consecuencias prácticas de aplicar la perspectiva social o la del financiador. El objetivo fue realizar una revisión sistemática para analizar si la inclusión/exclusión de los cuidados informales y/o pérdidas laborales influyen en los resultados y conclusiones de las EE.  Métodos: Se realizó una búsqueda sistemática en PubMed y Econlit para determinar las publicaciones que contenían EE sobre Alzheimer, Parkinson e Ictus. Criterios de inclusión: a) EE completas sobre las enfermedades en estudio; b) periodo enero 2006-julio 2016; y c) en inglés o español.  Resultados: Se obtuvieron 6.292 referencias, seleccionándose 245 artículos que podían cumplir los criterios de inclusión. Tras el análisis a texto completo, se seleccionaron 20 publicaciones de las cuales se obtuvieron 27 EE completas (20 corresponden a Alzheimer, 1 a Parkinson y 6 al Ictus). En 20 EE (74,1%) el cambio de perspectiva modifica los resultados, pasando a ser dominantes o incrementando el ahorro de recursos comparando las alternativas desde la perspectiva social. En las 7 restantes, la inclusión de los costes sociales supone un incremento en los costes de la intervención evaluada frente a su control. Únicamente en una EE varían las conclusiones al incluir los costes sociales.  Conclusiones: En general, la inclusión de los costes sociales puede modificar los resultados de las EE, pero su impacto sobre las conclusiones de las mismas es poco relevante.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background: In the field of the economic evaluation (EE), there is an open debate on the most appropriate perspective to apply. Despite the relevance of the topic, there are hardly any studies that have analyzed the practical consequences of applying the social perspective vs. health care funder. The aim of this study was performed a systematic review of the available evidence to analyze whether the inclusion/exclusion of informal care and/or loss of productivity influence the results and conclusions of economic evaluations.  Methods: A systematic review of the literature was carried out using PubMed and Econlit databases, to determine the publications that contained EE on Alzheimer, Parkinson and Stroke. Inclusion criteria were: a) full EE of the diseases under study; b) from January 2006-July 2016; and c) in English or Spanish.  Results: 6,292 references were identified, of which 245 publications meet the selection criteria and were analyzed. After the full-text analysis, 20 references were selected, of which 27 full EE were obtained (20 corresponding to Alzheimer, 1 to Parkinson and 6 to Stroke). In 20 EE (74.1%) the change of the perspective modifies the results, becoming dominant or increasing the saving of the resources by comparing the alternatives from the social perspective. In the remaining 7, the inclusion of social costs involves an increase in the costs of the intervention evaluated against its control. In a single EE, the conclusions vary when including social costs.  Conclusions: The inclusion of social costs can modify the results of EE but their impact on the conclusions is not relevant.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Evaluación económica]]></kwd>
<kwd lng="es"><![CDATA[Costes sociales]]></kwd>
<kwd lng="es"><![CDATA[Pérdidas laborales]]></kwd>
<kwd lng="es"><![CDATA[Cuidado informal]]></kwd>
<kwd lng="es"><![CDATA[Toma de decisiones]]></kwd>
<kwd lng="es"><![CDATA[Priorización]]></kwd>
<kwd lng="en"><![CDATA[Economic evaluation]]></kwd>
<kwd lng="en"><![CDATA[Social costs]]></kwd>
<kwd lng="en"><![CDATA[Loss of productivity]]></kwd>
<kwd lng="en"><![CDATA[Informal care]]></kwd>
<kwd lng="en"><![CDATA[Decision-making]]></kwd>
<kwd lng="en"><![CDATA[Prioritization]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Twenty Years of Using Economic Evaluations for Reimbursement Decisions. What Have We Achieved?]]></source>
<year>2002</year>
<numero>75</numero>
<issue>75</issue>
<publisher-loc><![CDATA[UK ]]></publisher-loc>
<publisher-name><![CDATA[Centre for Health Economics, University of York]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paris]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Belloni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Value in Pharmaceutical Pricing]]></source>
<year>2013</year>
<numero>63</numero>
<issue>63</issue>
<publisher-name><![CDATA[OECD]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[González-Zapata]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
<name>
<surname><![CDATA[Labeaga]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salud pública, economía y obesidad: el bueno, el feo y el malo]]></article-title>
<source><![CDATA[Gaceta Sanitaria]]></source>
<year>2008</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>507-10</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<source><![CDATA[Pla Interdepartamental de Salut Pública (PINSAP)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<source><![CDATA[Estrategia de Promoción de la Salud y Prevención en el Sistema Nacional de Salud]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antoñanzas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rivero-Arias]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación económica y la toma de decisiones en salud. El papel de la evaluación económica en la adopción y difusión de tecnologías sanitarias. Informe SESPAS 2008]]></article-title>
<source><![CDATA[Gac Sanit]]></source>
<year>2008</year>
<volume>22</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>137-42</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Espín]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cuestiones controvertidas en evaluación económica (i): perspectiva y costes de intervenciones sanitarias]]></article-title>
<source><![CDATA[Rev Esp Salud Pública]]></source>
<year>2015</year>
<volume>89</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-14</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A literature review of indirect costs associated with stroke]]></article-title>
<source><![CDATA[J Stroke Cerebrovasc Dis]]></source>
<year>2014</year>
<volume>23</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1753-63</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pares-Badell]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Barbaglia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jerinic]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost of disorders of the brain in Spain]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Luengo-Fernandez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic burden of cardiovascular diseases in the enlarged European Union]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2006</year>
<volume>27</volume>
<page-range>1610-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luengo-Fernandez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost of Dementia in the Pre-Enlargement Countries of the European Union]]></article-title>
<source><![CDATA[J Alzheimers Dis]]></source>
<year>2011</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>187-97</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luengo-Fernandez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic burden of cancer across the European Union: a population-based cost analysis]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2013</year>
<volume>14</volume>
<page-range>1165-74</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliva-Moreno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trapero-Bertran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Longobardo]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The valuation of informal care in cost-of-illness studies: a systematic review]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2017</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>331-45</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Bastida]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva-Moreno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Linertová]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Social/economic costs and health-related quality of life in patients with rare diseases in Europe]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2016</year>
<volume>17</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chari]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Engberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Opportunity Costs of Informal Elder-Care in the United States: New Estimates from the American Time Use Survey]]></article-title>
<source><![CDATA[Health Serv Res]]></source>
<year>2015</year>
<volume>50</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>871-82</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliva-Moreno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Loss of Labour Productivity Caused by Disease and Health Problems: What is the Magnitude of its Effect on Spain's Economy?]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2012</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>605-14</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Aranda]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva-Moreno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pérdidas laborales ocasionadas por los fallecimientos prematuros. Un análisis del periodo 2005-2009]]></article-title>
<source><![CDATA[Revista Española de Salud Pública]]></source>
<year>2015</year>
<volume>89</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-50</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arno]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Memmott]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The economic value of informal caregiving]]></article-title>
<source><![CDATA[Health Aff (Millwood)]]></source>
<year>1999</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>182-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña-Longobardo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aranda-Reneo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de las pérdidas laborales provocadas enfermedades y lesiones en España en el año 2009]]></article-title>
<source><![CDATA[Revista de Evaluación de Programas y Políticas Públicas]]></source>
<year>2016</year>
<volume>6</volume>
<page-range>66-85</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliva-Moreno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Longobardo]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Vilaplana-Prieto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An estimation of the value of informal care provided to dependent people in Spain]]></article-title>
<source><![CDATA[Appl Health Econ Health Policy]]></source>
<year>2015</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>223-31</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollander]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chappell]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Who Cares and How Much? The Imputed Economic Contribution to the Canadian Healthcare System of Middle-Aged and Older Unpaid Caregivers Providing Care to The Elderly]]></article-title>
<source><![CDATA[Healthc Q]]></source>
<year>2009</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>42-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paraponaris]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Davin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Verger]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formal and informal care for disabled elderly living in the community: an appraisal of French care composition and costs]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2012</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>327-36</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Papenburg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2016</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>391-402</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Papenburg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Exel]]></surname>
<given-names><![CDATA[J van]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2015</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>123-35</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<source><![CDATA[Site web de PRISMA.]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>Banco Central Europeo</collab>
<source><![CDATA[Statistical Data Warehouse]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<collab>International Monetary Fund</collab>
<source><![CDATA[World Economic Outlook Database]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[International Monetary Fund]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hornberger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Michalopoulos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective]]></article-title>
<source><![CDATA[J Ment Health Policy Econ]]></source>
<year>2015</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>63-73</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meeuwsen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Melis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aa]]></surname>
<given-names><![CDATA[G van der]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of one year dementia follow-up care by memory clinics or general practitioners: economic evaluation of a randomised controlled trial]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Touchon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lachaine]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beauchemin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2014</year>
<volume>15</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>791-800</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romeo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Knapp]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hellier]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial]]></article-title>
<source><![CDATA[Br J Psychiatry]]></source>
<year>2013</year>
<volume>202</volume>
<page-range>121-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfeil]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Kressig]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Szucs]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland]]></article-title>
<source><![CDATA[Swiss Med Wkly]]></source>
<year>2012</year>
<volume>142</volume>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Getsios]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation]]></article-title>
<source><![CDATA[BMC Neurol]]></source>
<year>2012</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lachaine]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beauchemin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Legault]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease]]></article-title>
<source><![CDATA[Can J Psychiatry]]></source>
<year>2011</year>
<volume>56</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>596-604</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rive]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aarsland]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Grishchenko]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway]]></article-title>
<source><![CDATA[Int J Geriatr Psychiatry]]></source>
<year>2012</year>
<volume>27</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>573-82</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Getsios]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Blume]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ishak]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom]]></article-title>
<source><![CDATA[Alzheimers Dement]]></source>
<year>2012</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-30</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brandtmüller]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models]]></article-title>
<source><![CDATA[Int J Geriatr Psychiatry]]></source>
<year>2011</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>483-94</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Getsios]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Blume]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ishak]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2010</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>411-27</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Bastida]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[García-Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease]]></article-title>
<source><![CDATA[J Alzheimers Dis]]></source>
<year>2009</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>399-407</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuh]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan]]></article-title>
<source><![CDATA[Int J Geriatr Psychiatry]]></source>
<year>2008</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-8</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weycker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Taneja]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Edelsberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2007</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1187-97</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Goodwin]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An exercise intervention to prevent falls in Parkinson's an economic evaluation]]></article-title>
<source><![CDATA[BMC Health Serv Res]]></source>
<year>2012</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barón Esquivias]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Escolar Albaladejo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zamorano]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis coste-efectividad de apixabán frente a acenocumarol en la prevención del ictus en pacientes con fibrilación auricular no vavular en España]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2015</year>
<volume>68</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>680-90</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Egri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mearns]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2016</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>488-95</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parody]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pedraza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[García-Gil]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-Utility Analysis of Magnetic Resonance Imaging Management of Patients with Acute Ischemic Stroke in a Spanish Hospital]]></article-title>
<source><![CDATA[Neurol Ther]]></source>
<year>2015</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-37</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doan]]></surname>
<given-names><![CDATA[QV]]></given-names>
</name>
<name>
<surname><![CDATA[Gillard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brashear]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland]]></article-title>
<source><![CDATA[Eur J Neurol]]></source>
<year>2013</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>773-80</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Juanatey]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Sabin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lobos]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistemática en fibrilación auricular no valvular en España]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2012</year>
<volume>65</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>901-10</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Bastida]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antoñanzas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias]]></article-title>
<source><![CDATA[Gaceta Sanitaria]]></source>
<year>2010</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>154-70</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="">
<collab>National Health Care Institute (ZIN)</collab>
<source><![CDATA[Guideline for the Conduct of Economic Evaluations in Health Care]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="">
<collab>The Dental and Pharmaceutical Benefits Agency (TLV)</collab>
<source><![CDATA[General guidelines for economic evaluations from (2003)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="">
<collab>Norwegian Medicines Agency (Statens legemiddelverk)</collab>
<source><![CDATA[Guidelines on how to conduct pharmacoeconomic. Analyses]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="book">
<collab>Haute Autorité de Santé (HAS)</collab>
<source><![CDATA[A Methodological Guide. Choices in Methods for Economic Evaluation]]></source>
<year>2012</year>
<publisher-loc><![CDATA[France ]]></publisher-loc>
<publisher-name><![CDATA[Department of Economics and Public Health Assessment]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puig-Junoy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva-Moreno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trapero-Bertrán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía y recomendaciones para la realización y presentación de evaluaciones económicas y análisis de impacto presupuestario de medicamentos en el ámbito del CatSalut]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Generalitat de Catalunya. Departament de Salut. Servei Català de la Salut]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saltman]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Dubois]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
<name>
<surname><![CDATA[Chawla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of aging on long-term care in Europe and some potential policy responses]]></article-title>
<source><![CDATA[Int J Health Serv]]></source>
<year>2006</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>719-46</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Forder]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trukeschitz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[How can European states design efficient, equitable and sustainable funding systems for long-term care for older people?]]></source>
<year>2009</year>
<numero>11</numero>
<issue>11</issue>
<publisher-loc><![CDATA[Copenhagen ]]></publisher-loc>
<publisher-name><![CDATA[WHO Regional Office for Europe. European Observatory on Health Systems and Policies]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Triantafillou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Naiditch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Repkova]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Informal care in the long-term care system]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Athens ]]></publisher-loc>
<publisher-name><![CDATA[Health systems and longterm care for older people in Europe-INTERLINKS Project]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Exel]]></surname>
<given-names><![CDATA[J van]]></given-names>
</name>
<name>
<surname><![CDATA[Bobinac]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Koopmanschap]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The invisible hands made visible: recognizing the value of informal care in healthcare decision-making]]></article-title>
<source><![CDATA[Expert Rev Pharmacoecon Outcomes Res]]></source>
<year>2008</year>
<volume>8</volume>
<page-range>557-61</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoefman]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Exel]]></surname>
<given-names><![CDATA[J van]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to include informal care in economic evaluations]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2013</year>
<volume>31</volume>
<page-range>1105-19</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa-Poza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacts of Informal Caregiving on Caregiver Employment, Health, and Family]]></article-title>
<source><![CDATA[Journal of Population Ageing]]></source>
<year>2015</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>113-45</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yabroff]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Time costs associated with informal caregiving for cancer survivors]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2009</year>
<volume>115</volume>
<page-range>4362-73</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
